South Korea
Market insights
South Korea has one of the largest pharmaceutical markets in Asia, with more than 50 million South Koreans receiving prescription drug coverage under the single-payer National Health Insurance (NHI) program. The NHI is under the purview of The Ministry of Health and Welfare (MOHW), which also oversees the South Korean FDA, responsible for drug approvals, and the Health Insurance Review and Assessment Service (HIRA), which determines a drug’s reimbursement.
The South Korean drug marketing landscape is tightly regulated by the Pharmaceutical Affairs Act (PAA) with clearly defined regulations for consumer and clinical advertising. While there are no specific regulations pertaining to social media, promotion related to medicinal drugs must be conducted according to regulations.
TO Pharma
Marketing Codes
TO Market Access
Sign up to get the guides
Select the guides you wish to download
Our office in South Korea
Founded in 2015, PR Bom is a healthcare-focused communications agency that delivers practical, effective solutions by combining deep regulatory expertise with a client-centric approach. Operating within South Korea’s complex healthcare environment—characterized by a universal national health insurance system, a ban on direct-to-consumer (DTC) advertising, and a layered reimbursement framework—PR Bom has earned a strong reputation for its strategic communications and consistent results.